Whitepapers

Whitepaper Aug 4, 2021

An Introduction to Planning for HTA for Tumour-Agnostic Cancer Drugs

Whitepaper May 19, 2021

Are There Only 10 Commercial Strategies in Pharma?

Whitepaper May 13, 2021

Connecting the Dots: Harnessing Real World Data in Healthcare Decision Making

Whitepaper Apr 29, 2021

Next Wave Anti-Cancer Therapies: Part 1

Whitepaper Apr 26, 2021

Five Learnings Manufacturers Should Take from the Latest NICE Guidance on Survival Modelling

Whitepaper Mar 19, 2021

Navigating the Post-COVID Landscape

Whitepaper Jan 29, 2021

Accelerating Access to New Innovative Treatments: Lessons From COVID-19

Whitepaper Jan 28, 2021

How Are Medical Affairs Organizations Proving Their Value?

Whitepaper Nov 27, 2020

How the Latest NICE Methods Consultation Could Impact Your Evidence Generation Strategy

Whitepaper Oct 30, 2020

‘Excel cannot complete this task’: Drawing parallels between UK Test and Trace and health economic models

Whitepaper Oct 23, 2020

Navigating the Assessment of CAR T-Cell Therapies: Stepping Back to Look Forwards

Whitepaper Aug 21, 2020

NICE Technical Engagement Process: Navigating the Latest Changes

Whitepaper Jul 8, 2020

Demonstrating the Value of Drugs for Rare Diseases – 8 Common Challenges and How to Address Them Before They Arise

Whitepaper May 27, 2020

How to Apply for an FDA Coronavirus Emergency Use Authorization Letter

Whitepaper Apr 16, 2020

New Talc and Mesothelioma Studies Provide Unique Risks and Opportunities for Defendants and Insurers

1 … 5 6 7